We discover and develop our drugs both independently and in collaboration with pharmaceutical, biotechnology and academic partners. In all our partner collaborations we apply our proprietary technologies, including IntelliSelect™ Transgenic and IntelliSelect™ Screening, to discover, develop and commercialise monoclonal antibodies to difficult and novel drug targets in our therapeutic areas of immuno-oncology, haematology, inflammation and infectious disease.
We have mature partnerships to develop products that serve patients with high unmet medical needs. Our partners access our team of proven drug-discovery and development scientists employing our suite of proprietary technologies including:
our unique antibody discovery and development platforms (for both monospecific and bispecific antibodies) that rapidly generate candidate-quality antibodies with the desired affinity, potency, epitope binding, mechanism of action and biophysical properties; our IntelliSelect™ Screening platform that deeply mines the output from our IntelliSelectTM Transgenic platforms and isolates candidate-quality molecules; our efficient systems to add or remove genes or sequences to pursue challenging drug targets and achieve species cross-reactivity that avoids the need for surrogate molecules in pre-clinical testing.
We are passionate to pursue new collaborations and partnerships that maximise value and impact on patients' lives.
To find out more, please contact: email@example.com